Together, these results shed light into the context-specific responses of apalutamide when used as combination therapy with AKT inhibition in PTEN-deficient prostate cancer and provide additional evidence to further explore additional combination approaches to improve apalutamide therapeutic responses. Here, AKT1 is linked to prostate carcinoma.